Aclarion (ACON) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
28 Apr, 2026Executive summary
The annual meeting is scheduled for June 4, 2026, with voting on director elections, auditor ratification, and an amendment to the equity incentive plan.
Only stockholders of record as of April 10, 2026, are eligible to vote, with 2,462,250 shares outstanding.
Proxy materials and annual reports are available online and by request.
Voting matters and shareholder proposals
Seven director nominees are up for election to serve until the 2027 annual meeting.
Ratification of Haynie & Company as independent auditor for fiscal year ending December 31, 2026.
Approval sought for an amendment to the 2022 Equity Incentive Plan, increasing the share reserve and annual grant limits.
Shareholders may submit proposals for the 2027 meeting by December 28, 2026, for inclusion in proxy materials.
Board of directors and corporate governance
The board consists of seven members, with a majority deemed independent under Nasdaq and SEC rules.
Three standing committees: audit, compensation, and nominating/corporate governance, each with independent chairs.
The nominating committee values diversity and considers stockholder recommendations for director nominees.
Board and committees met regularly in 2025, with all directors attending at least 75% of meetings.
A code of business conduct and ethics applies to all directors, officers, and employees.
Latest events from Aclarion
- Nociscan pairs chemical disc diagnostics with a funded, outcomes-focused scale-up.ACON
LD Micro 20th Annual Main Event Conference - AI-driven NOCISCAN platform accelerates clinical and commercial growth in the global back pain market.ACON
Lytham Partners Fall 2026 Investor Conference - Q2 2026 revenue rose 30.5% year-over-year, but net loss widened on higher operating costs.ACON
Q2 2026 - AI-powered biomarkers may revolutionize spine surgery accuracy and payer adoption.ACON
Planet MicroCap Las Vegas 2026 - Revenue up 11% year-over-year, but net loss widened on higher expenses; cash supports growth plans.ACON
Q1 2026 - Shareholders will vote on director elections, auditor ratification, and a major equity plan amendment.ACON
Proxy filing - Revenue up 65.6% to $75.7K; net loss $7.2M; $22.6M raised in 2025, $10.4M in 2026.ACON
Q4 2025 - Non-invasive spinal diagnostics see clinical, commercial, and reimbursement momentum in key markets.ACON
Investor Update - Innovative MRI-based diagnostics for back pain gain traction with strong evidence and payer support.ACON
Planet MicroCap Showcase VEGAS 2025